Biofrontera AG Statistics

Total Valuation

Biofrontera AG has a market cap or net worth of EUR 15.50 million. The enterprise value is 13.14 million.

Market Cap	15.50M
Enterprise Value	13.14M

Important Dates

The next estimated earnings date is Saturday, May 31, 2025.

Earnings Date	May 31, 2025
Ex-Dividend Date	n/a

Share Statistics

Biofrontera AG has 6.08 million shares outstanding. The number of shares has increased by 100.00% in one year.

Current Share Class	6.08M
Shares Outstanding	6.08M
Shares Change (YoY)	+100.00%
Shares Change (QoQ)	-2.09%
Owned by Insiders (%)	62.32%
Owned by Institutions (%)	7.34%
Float	1.39M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.72
PB Ratio	0.82
P/TBV Ratio	0.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-3.02
EV / Sales	0.61
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-4.78

Financial Position

The company has a current ratio of 1.55, with a Debt / Equity ratio of 0.04.

Current Ratio	1.55
Quick Ratio	0.92
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	-0.28
Interest Coverage	-540.18

Financial Efficiency

Return on equity (ROE) is -22.40% and return on invested capital (ROIC) is -18.23%.

Return on Equity (ROE)	-22.40%
Return on Assets (ROA)	-12.30%
Return on Invested Capital (ROIC)	-18.23%
Return on Capital Employed (ROCE)	-30.97%
Revenue Per Employee	246,205
Profits Per Employee	-49,432
Employee Count	88
Asset Turnover	0.72
Inventory Turnover	1.00

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -64.49% in the last 52 weeks. The beta is 0.16, so Biofrontera AG's price volatility has been lower than the market average.

Beta (5Y)	0.16
52-Week Price Change	-64.49%
50-Day Moving Average	2.44
200-Day Moving Average	2.48
Relative Strength Index (RSI)	55.07
Average Volume (20 Days)	1,631

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Biofrontera AG had revenue of EUR 21.67 million and -4.35 million in losses. Loss per share was -0.72.

Revenue	21.67M
Gross Profit	16.34M
Operating Income	-5.94M
Pretax Income	-6.72M
Net Income	-4.35M
EBITDA	-5.70M
EBIT	-5.94M
Loss Per Share	-0.72

Full Income Statement

Balance Sheet

The company has 3.12 million in cash and 765,000 in debt, giving a net cash position of 2.36 million or 0.39 per share.

Cash & Cash Equivalents	3.12M
Total Debt	765,000
Net Cash	2.36M
Net Cash Per Share	0.39
Equity (Book Value)	18.86M
Book Value Per Share	3.10
Working Capital	5.79M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -2.54 million and capital expenditures -210,000, giving a free cash flow of -2.75 million.

Operating Cash Flow	-2.54M
Capital Expenditures	-210,000
Free Cash Flow	-2.75M
FCF Per Share	-0.45

Full Cash Flow Statement

Margins

Gross margin is 75.41%, with operating and profit margins of -27.43% and -20.08%.

Gross Margin	75.41%
Operating Margin	-27.43%
Pretax Margin	-31.01%
Profit Margin	-20.08%
EBITDA Margin	-26.31%
EBIT Margin	-27.43%
FCF Margin	n/a

Dividends & Yields

Biofrontera AG does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-100.00%
Shareholder Yield	-100.00%
Earnings Yield	-28.07%
FCF Yield	-17.74%

Stock Splits

The last stock split was on May 14, 2024. It was a reverse split with a ratio of 0.047619.

Last Split Date	May 14, 2024
Split Type	Reverse
Split Ratio	0.047619

Scores

Biofrontera AG has an Altman Z-Score of -4.56. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.56
Piotroski F-Score	n/a